Table 2.

Selected Characteristics of Boceprevir and Telaprevir

	Boceprevir	Telaprevir
4-week peginterferon alfa/ribavirin lead-in	Yes	No
PI duration HCV treatment-naive	24 weeks or 44 weeks	12 weeks
HCV treatment- experienced	32 weeks or 44 weeks	12 weeks
Criterion for RGT*	RNA-negative at weeks 8-24	RNA-negative at week 4 and week 12
RGT-eligible, treatment- naive patients	~44%	~58%-65%
RGT-eligible, treatment- experienced patients	Relapsers and partial responders (null responders not eligible)	Relapsers (partial and null responders not eligible)
Total duration of treatment in treatment- experienced patients	36 weeks (with eRVR) or 48 weeks	24 weeks or 48 weeks
Stopping rule for futility	HCV RNA > 100 IU/mL at week 12	HCV RNA > 1000 IU/mL at week 4 or week 12
	Detectable virus at week 24	Detectable virus at week 24
Added adverse effects	Anemia, dysgeusia	Anemia, rash, pruritus, nausea, diarrhea
Dosage	Four 200 mg pills every 8 hours	Two 375 mg pills every 8 hours
Food requirement	Must be taken with some food	Must be taken with meal containing ≥ 20 g of fat

^*RGT indicates response-guided therapy; PI, protease inhibitor; eRVR, early rapid virologic response. RGT is not recommended in patients with cirrhosis or HIV coinfection.